98%
921
2 minutes
20
Clinical trials continue to disproportionately underrepresent people of color. Increasing representation of diverse backgrounds among clinical research personnel has the potential to yield greater representation in clinical trials and more efficacious medical interventions by addressing medical mistrust. In 2019, North Carolina Central University (NCCU), a Historically Black College and University with a more than 80% underrepresented student population, established the Clinical Research Sciences Program with support from the Clinical and Translational Science Awards (CTSA) program at neighboring Duke University. This program was designed to increase exposure of students from diverse educational, racial, and ethnic backgrounds to the field of clinical research, with a special focus on health equity education. In the first year, the program graduated 11 students from the two-semester certificate program, eight of whom now hold positions as clinical research professionals. This article describes how leveraging the CTSA program helped NCCU build a framework for producing a highly trained, competent, and diverse workforce in clinical research responsive to the call for increased diversity in clinical trial participation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947598 | PMC |
http://dx.doi.org/10.1017/cts.2022.489 | DOI Listing |
J Clin Transl Sci
July 2025
Wright Regional Center for Clinical and Translational Science, Virginia Commonwealth University, Richmond, VA, USA.
Mentorship is a vital part of the training provided in the K and T programs funded by the Clinical and Translational Science Awards (CTSA). However, the inputs, indicators, and outcomes associated with a successful mentoring relationship remain poorly understood. In this review, we critically examine the current body of literature on mentorship in a CTSA context.
View Article and Find Full Text PDFFront Public Health
August 2025
Clinical and Translational Science Collaborative of Northern Ohio, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
The Clinical and Translational Science Award (CTSA) program, funded by the National Center for Advancing Translational Sciences (NCATS), aims to accelerate the translation of research into public health impacts. However, measuring the societal impact of translational research poses challenges due to extended timelines for implementation. This study uses the Translational Science Benefits Model (TSBM) to evaluate the societal impact of CTSA-supported research at the Clinical and Translational Science Collaborative (CTSC) of Northern Ohio at Case Western Reserve University (CWRU).
View Article and Find Full Text PDFJACC Adv
August 2025
Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA.
Background: Chronic kidney disease (CKD) is a risk-enhancing factor for cardiovascular disease (CVD) and is associated with higher lipoprotein(a) (Lp[a]) levels. While aspirin may reduce Lp(a)-related prothrombotic risk, the role of primary prevention aspirin for persons with CKD and elevated Lp(a) is unclear.
Objectives: The aim of the study was to assess the association of aspirin use with cardiovascular, renal, and bleeding outcomes stratified by Lp(a) level among individuals with CKD without clinical CVD.
Gynecol Oncol
August 2025
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Medicine, Weill Cornell Medical College, New York, NY, United States of America; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Slo
Objective: To characterize age-related variations in germline pathogenic variants (gPVs) in patients with high-grade serous ovarian cancer (HGSOC).
Methods: Patients with HGSOC who underwent clinical tumor-normal sequencing of ≥76 genes from 1/1/2015-11/15/2022, were included. Clinical variables including age at diagnosis were collected.
JACC Clin Electrophysiol
July 2025
Department of Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiovascular Medicine, Divisions of Heart Rhythm Services and Circulatory Failure, Windland Smith Rice Genetic Heart Rhythm